Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Nov;65(10):1421-1430.
doi: 10.1111/aas.13941. Epub 2021 Sep 20.

Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trial

Marie Warrer Munch  1   2 , Tine Sylvest Meyhoff  1   2 , Marie Helleberg  3 , Maj-Brit Nørregaard Kjaer  1   2 , Anders Granholm  1   2 , Carl Johan Steensen Hjortsø  1   2 , Thomas Steen Jensen  1   2 , Morten Hylander Møller  1   2 , Peter Buhl Hjortrup  1   2 , Mik Wetterslev  1   2 , Gitte Kingo Vesterlund  1   2 , Lene Russell  1   2 , Vibeke Lind Jørgensen  4 , Klaus Tjelle Kristiansen  5 , Thomas Benfield  6 , Charlotte Suppli Ulrik  7 , Anne Sofie Andreasen  8 , Morten Heiberg Bestle  2   9   10 , Lone Musaeus Poulsen  11 , Thomas Hildebrandt  12 , Lene Surland Knudsen  13 , Anders Møller  14 , Christoffer Grant Sølling  15 , Anne Craveiro Brøchner  16 , Bodil Steen Rasmussen  2   17 , Henrik Nielsen  18 , Steffen Christensen  19 , Thomas Strøm  20 , Maria Cronhjort  21 , Rebecka Rubenson Wahlin  21 , Stephan M Jakob  22 , Luca Cioccari  22 , Balasubramanian Venkatesh  23   24 , Naomi Hammond  23 , Vivekanand Jha  24   25   26 , Sheila Nainan Myatra  27 , Marie Qvist Jensen  1 , Jens Wolfgang Leistner  1 , Vibe Sommer Mikkelsen  1 , Jens S Svenningsen  1 , Signe Bjørn Laursen  1 , Emma Victoria Hatley  1 , Camilla Meno Kristensen  1 , Ali Al-Alak  6 , Esben Clapp  6 , Trine Bak Jonassen  6 , Caroline Løkke Bjerregaard  9 , Niels Christian Haubjerg Østerby  9 , Mette Mindedahl Jespersen  9 , Dalia Abou-Kassem  8 , Mathilde Languille Lassen  8 , Reem Zaabalawi  14 , Mohammed Mahmoud Daoud  14 , Suhayb Abdi  14 , Nick Meier  1 , Kirstine la Cour  11 , Cecilie Bauer Derby  11 , Birka Ravnholt Damlund  11 , Jens Laigaard  11 , Lene Lund Andersen  16 , Johan Mikkelsen  16 , Jeppe Lundholm Stadarfeld Jensen  16 , Anders Hørby Rasmussen  15 , Emil Arnerlöv  15 , Mathilde Lykke  15 , Mikkel Zacharias Bystrup Holst-Hansen  19 , Boris Wied Tøstesen  19 , Janne Schwab  19   28 , Emilie Kabel Madsen  19 , Christian Gluud  29   30 , Theis Lange  31 , Anders Perner  1   2
Affiliations
Randomized Controlled Trial

Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trial

Marie Warrer Munch et al. Acta Anaesthesiol Scand. 2021 Nov.

Abstract

Background: In the early phase of the pandemic, some guidelines recommended the use of corticosteroids for critically ill patients with COVID-19, whereas others recommended against the use despite lack of firm evidence of either benefit or harm. In the COVID STEROID trial, we aimed to assess the effects of low-dose hydrocortisone on patient-centred outcomes in adults with COVID-19 and severe hypoxia.

Methods: In this multicentre, parallel-group, placebo-controlled, blinded, centrally randomised, stratified clinical trial, we randomly assigned adults with confirmed COVID-19 and severe hypoxia (use of mechanical ventilation or supplementary oxygen with a flow of at least 10 L/min) to either hydrocortisone (200 mg/d) vs a matching placebo for 7 days or until hospital discharge. The primary outcome was the number of days alive without life support at day 28 after randomisation.

Results: The trial was terminated early when 30 out of 1000 participants had been enrolled because of external evidence indicating benefit from corticosteroids in severe COVID-19. At day 28, the median number of days alive without life support in the hydrocortisone vs placebo group were 7 vs 10 (adjusted mean difference: -1.1 days, 95% CI -9.5 to 7.3, P = .79); mortality was 6/16 vs 2/14; and the number of serious adverse reactions 1/16 vs 0/14.

Conclusions: In this trial of adults with COVID-19 and severe hypoxia, we were unable to provide precise estimates of the benefits and harms of hydrocortisone as compared with placebo as only 3% of the planned sample size were enrolled.

Trial registration: ClinicalTrials.gov: NCT04348305. European Union Drug Regulation Authorities Clinical Trials (EudraCT) Database: 2020-001395-15.

Keywords: COVID-19; SARS-CoV-2; corticosteroids; hydrocortisone; placebo-controlled trial; randomised clinical trial.

PubMed Disclaimer

Conflict of interest statement

The Department of Intensive Care, Rigshospitalet, has received funds for other research projects from the Novo Nordisk Foundation, Ferring and Fresenius Kabi. TB reports grants from Novo Nordisk Foundation, grants from Lundbeck Foundation, grants from Simonsen Foundation, grants and personal fees from GSK, grants and personal fees from Pfizer, personal fees from Boehringer Ingelheim, grants and personal fees from Gilead, personal fees from MSD, grants from Kai Hansen Foundation, outside the submitted work. CSU has received personal fees from AstraZeneca, GSK, Chiesi, TEVA, ALK‐Abello, Orion Pharma, Boehringer‐Ingelheim, Sanofi‐Genzyme, Novartis and Actelion outside the submitted work. The Department of Intensive Care Medicine, Bern University Hospital (Inselspital), has or has had research & development/consulting contracts with Edwards Lifesciences Services GmbH, Phagenesis Limited and Nestlé. The money was paid into a departmental fund, and none of the authors received any financial gain. The Department of Intensive Care Medicine, Bern University Hospital (Inselspital), has received unrestricted educational grants from the following organisations for organising bi‐annual postgraduate courses in the fields of critical care ultrasound, management of extracorporeal membrane oxygenation (ECMO) and mechanical ventilation: Pierre Fabre Pharma AG (formerly known as RobaPharm), Pfizer AG, Bard Medica SA, Abbott AG, Anandic Medical Systems, PanGas AG Healthcare, Orion Pharma, Bracco, Edwards Lifesciences AG, Hamilton Medical AG, Fresenius Kabi (Schweiz) AG, Getinge Group Maquet AG, Dräger Schweiz AG, and Teleflex Medical GmbH. The remaining authors have no conflicts of interest to declare.

Figures

FIGURE 1
FIGURE 1
Screening, allocation and follow‐up [Colour figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. Coronaviridae Study Group of the International Committee on Taxonomy of V . The species severe acute respiratory syndrome‐related coronavirus: classifying 2019‐nCoV and naming it SARS‐CoV‐2. Nat Microbiol. 2020;5:536‐544. - PMC - PubMed
    1. World Health Organization . Novel Coronavirus (2019‐nCoV). Situation Report 22. https://www.who.int/docs/default‐source/coronaviruse/situation‐reports/2.... Accessed on March 18, 2020.
    1. Pascarella G, Strumia A, Piliego C, et al. COVID‐19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288:192‐206. - PMC - PubMed
    1. Rygard SL, Butler E, Granholm A, et al. Low‐dose corticosteroids for adult patients with septic shock: a systematic review with meta‐analysis and trial sequential analysis. Intensive Care Med. 2018;44:1003‐1016. - PubMed
    1. Sun S, Liu D, Zhang H, Zhang X, Wan B. Effect of different doses and time‐courses of corticosteroid treatment in patients with acute respiratory distress syndrome: a meta‐analysis. Exp Ther Med. 2019;18:4637‐4644. - PMC - PubMed

Publication types

Associated data